Serlopitant tablet (DrugBank: Serlopitant)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03836001 (ClinicalTrials.gov) | April 18, 2019 | 7/2/2019 | A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Epidermolysis Bullosa | Drug: Serlopitant Tablet;Drug: Placebo Oral Tablet | Stanford University | Epidermolysis Bullosa Research Partnership;Menlo Therapeutics | Recruiting | 13 Years | N/A | All | 40 | Phase 2 | United States |